Preparation and characterization of simvastatin/hydroxypropyl-β-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process

被引:209
作者
Jun, Seoung Wook
Kim, Min-Soo
Kim, Jeong-Soo
Park, Hee Jun
Lee, Sibeum
Woo, Jong-Soo
Hwang, Sung-Joo
机构
[1] Chungnam Natl Univ, Natl Res Lab Pharmaceut Technol, Coll Pharm, Taejon 305764, South Korea
[2] Hanmi Pharmaceut Co Ltd, Kyonggi Do, South Korea
关键词
simvastatin; hydroxypropyl-beta-cyclodextrin; inclusion complex; supercritical antisolvent (SAS) process;
D O I
10.1016/j.ejpb.2006.11.013
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
In the present study, the practically insoluble drug, simvastatin (SV), and its inclusion complex with hydroxypropyl beta-cyclodextrin (HP-beta-CD) prepared using supercritical antisolvent (SAS) process were investigated to improve the aqueous solubility and the dissolution rate of drug, thus enhancing its bioavailability. Inclusion complexation in aqueous solution and solid state was evaluated by the phase solubility diagram, differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD), Fourier-transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM). The phase solubility diagram with HP-beta-CD was classified as A(L)-type at all temperatures investigated, indicating the formation of 1:1 stoichiometric inclusion complex. The apparent complexation constants (K-1:1) calculated from phase solubility diagram were 774, 846 and 924 M-1 at 25, 37 and 45 +/- 0.5 degrees C, respectively. No endothermic and characteristic diffraction peaks corresponding to SV was observed for the inclusion complex in DSC and PXRD. FT-IR study demonstrated the presence of inter-molecular hydrogen bonds between SV and HP-beta-CD in inclusion complex, resulting in the formation of amorphous form. Aqueous solubility and dissolution studies indicated that the dissolution rates were remarkably increased in inclusion complex, compared with the physical mixture and drug alone. Moreover, SV/HP-beta-CD inclusion complex performed better than SV in reducing total cholesterol and triglyceride levels. This could be primarily attributed to the improved solubility and dissolution associated with inclusion complex between drug and HP-beta-CD. In conclusion, SAS process could be a useful method for the preparation of the inclusion complex of drug with HP-beta-CD and its solubility, dissolution rate and hypolipidernic activity were significantly increased by complexation between SV and HP-beta-CD. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:413 / 421
页数:9
相关论文
共 26 条
[1]
Phase solubility and inclusion complex of itraconazole with β-cyclodextrin using supercritical carbon dioxide [J].
Al-Marzouqi, AH ;
Shehatta, I ;
Jobe, B ;
Dowaidar, A .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (02) :292-304
[2]
Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug:: In vitro and in vivo evaluations [J].
Ambike, AA ;
Mahadik, KR ;
Paradkar, A .
PHARMACEUTICAL RESEARCH, 2005, 22 (06) :990-998
[3]
Preparation of budesonide- and indomethacin-hydroxypropyl-β-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process [J].
Bandi, N ;
Wei, W ;
Roberts, CB ;
Kotra, LP ;
Kompella, UB .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 23 (02) :159-168
[4]
Utilization of supercritical carbon dioxide for complex formation of ibuprofen and methyl-β-cyclodextrin [J].
Charoenchaitrakool, M ;
Dehghani, F ;
Foster, NR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 239 (1-2) :103-112
[5]
EVALUATION OF SUSTAINED CONTROLLED-RELEASE DOSAGE FORMS OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A (HMG-COA) REDUCTASE INHIBITORS IN DOGS AND HUMANS [J].
CHENG, HY ;
SUTTON, SC ;
PIPKIN, JD ;
ZENTNER, GM ;
ROGERS, JD ;
SCHWARTZ, JI ;
MITCHEL, YB ;
GRASING, K ;
SCHWARTZ, MS ;
AMIN, RD ;
LIU, L ;
EBEL, DL ;
COULTER, A ;
ENGLE, K ;
MCCLELLAND, GA ;
LUI, CY ;
RORK, GS .
PHARMACEUTICAL RESEARCH, 1993, 10 (11) :1683-1687
[6]
INCLUSION COMPLEXATION OF GLIBENCLAMIDE WITH 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN IN SOLUTION AND IN SOLID-STATE [J].
ESCLUSADIAZ, MT ;
TORRESLABANDEIRA, JJ ;
KATA, M ;
VILAJATO, JL .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 1 (06) :291-296
[7]
Particle generation for pharmaceutical applications using supercritical fluid technology [J].
Fages, J ;
Lochard, H ;
Letourneau, JJ ;
Sauceau, M ;
Rodier, E .
POWDER TECHNOLOGY, 2004, 141 (03) :219-226
[8]
IMPROVEMENT OF THE INVITRO DISSOLUTION CHARACTERISTICS OF FAMOTIDINE BY INCLUSION IN BETA-CYCLODEXTRIN [J].
HASSAN, MA ;
SULEIMAN, MS ;
NAJIB, NM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 58 (01) :19-24
[9]
Higuchi T., 1965, Interscience, New York, V4, P117
[10]
Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids [J].
Jun, SW ;
Kim, MS ;
Jo, GH ;
Lee, S ;
Woo, JS ;
Park, JS ;
Hwang, SJ .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (12) :1529-1537